Studying the Immunomodulatory Effects of Small Molecule Ras Inhibitors in Animal Models of Rheumatoid Arthritis
Abstract
During the three year of the award, our major research achievements/findings were as follows:(i) Farnesylthiosalicylic acid (FTS) therapy, a first-in-class oral selective RAS inhibitor, provides a significant immunomodulatory effect in the rat adjuvant-induced arthritis (AIA)model by all clinical and laboratory outcome parameters. (ii) Therapy with FTS as an add-onto the drug methotrexate (MTX) provides a superior protective effect compared to monotherapy.(iii) In the AIA model the FTS derivative, F-FTS, showed higher therapeutic efficacy compared to FTS. (iv) The functional genomics studies showed that FTS therapy inhibits the in vivoTH17 immune response.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2017
- Accession Number
- AD1047306
Entities
People
- Einav Vax
- Galit E. Sfadia
- Itamar Goldstein
- Itzhak B. Moshe
- Morad Zayoud
- Ronit Pinkas-kramarski
- Yoel Kloog
Organizations
- Tel Aviv University